长风药业获NMPA批准开展盐酸奥洛他定与糠酸莫米松一水合物鼻喷雾剂临床试验

美股速递
Mar 09

长风药业股份有限公司宣布,其研发的盐酸奥洛他定与糠酸莫米松一水合物鼻喷雾剂已获得国家药品监督管理局(NMPA)的临床试验申请批准。这一进展标志着该药物正式进入临床研究阶段,为公司产品管线增添了重要一员。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10